Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs IQIYI Inc - ADR (IQ) Price & Performance

BioNTech SE - ADRTrade
IQIYI Inc - ADRTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs IQIYI Inc - ADR — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while IQIYI Inc - ADR trades at $1.34 (market cap $1.30B). The key difference: BioNTech SE - ADR is far larger — about 17.9× IQIYI Inc - ADR's market cap. Which is the better fit depends on your goals.

BNTXIQ
Market Cap
$23.31B$1.30B
Sector
HealthMedia
52-Week High
$119.34$2.79
52-Week Low
$83.89$0.96
Enterprise Value
$6.60B$2.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

IQIYI Inc - ADR

IQ trades at $1.325, down 2.57% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two recent quarters. Analyst sentiment is mixed with a 50% buy rating, while news highlights AI platform growth and leadership changes as potential catalysts.

The outlook hinges on IQ's AI-driven content strategy and cost management reversing profitability declines. Risks include intense competition, regulatory pressures in China, and sustained negative cash flow projections for 2026. Upside potential exists if execution improves, but high debt and margin pressures warrant caution for investors.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About IQIYI Inc - ADR

iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.

Read more on IQ